The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers.
 
Mairead Geraldine McNamara
Consulting or Advisory Role - Celgene; Ipsen
Research Funding - Nucana
Induction Chemotherapy (Ind CT) Followed by Concomitant Chemoradiotherapy (CXRT) for Stage IV Head and Neck Cancer (HNC): An Attempt at Locoregional and Systemic Tumor Control.
 
John A. Bridgewater
Honoraria - Merck Serono; SERVIER
Consulting or Advisory Role - Merck Serono; Roche; SERVIER
Speakers' Bureau - Celgene
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology; SERVIER
 
Daniel H. Palmer
Research Funding - Nucana
 
Harpreet Singh Wasan
Honoraria - Array BioPharma; Celgene; Lilly; Merck KGaA; Servier; Sirtex Medical
Speakers' Bureau - Celgene; Merck KGaA; Sirtex Medical
Research Funding - Merck KGaA (Inst); Pfizer (Inst); Sirtex Medical (Inst)
 
David Ryder
No Relationships to Disclose
 
Chathunissa Gnanaranjan
No Relationships to Disclose
 
Essam Ahmed Ghazaly
No Relationships to Disclose
 
T.R. Jeffry Evans
Research Funding - AstraZeneca
 
Juan W. Valle
Consulting or Advisory Role - Agios; AstraZeneca; Baxalta; Delcath Systems; Ipsen; Lilly; Merck; Midatech Pharma; Novartis; Pfizer
Speakers' Bureau - Celgene; Novartis; Pfizer
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Lilly; Novartis